current
antivir
treatment
limit
efficaci
sever
viral
infect
includ
caus
hepat
virus
respiratori
virus
human
immunodefici
viru
hiv
herpesvirus
necessit
identif
improv
therapeut
option
quest
novel
potent
antivir
agent
continu
strategi
combin
antivir
therapi
avail
antivir
drug
potenti
benefici
fact
proven
use
number
viral
diseas
enhanc
antivir
efficaci
combin
treatment
mediat
synergist
addit
activ
combin
antivir
activ
broad
rang
viral
reservoir
broad
coverag
establish
resist
viral
popul
prevent
antivir
resist
addit
combin
treatment
two
synergist
activ
drug
may
enabl
dose
reduct
toxic
compon
combin
consensu
symposium
combin
antivir
therapi
organ
conven
macra
group
new
york
citi
ny
usa
review
progress
field
combin
therapi
varieti
viral
diseas
make
recommend
futur
use
potenti
effect
combin
avail
antivir
drug
de
jong
et
al
view
rapidli
evolv
field
antivir
therapi
second
edit
success
meet
organ
macra
group
barcelona
spain
septemb
lead
research
laboratori
clinic
field
review
success
limit
current
antivir
monotherapi
statu
combin
therapi
articl
provid
review
inform
present
symposium
appropri
consensu
reach
certain
area
base
inform
laboratori
usa
hc
lane
nation
institut
health
usa
j
van
hattum
univers
hospit
utrecht
netherland
b
gazzard
chelsea
westminst
hospit
uk
r
schuurman
utrecht
univers
netherland
symposium
sponsor
intern
societi
antivir
research
nation
foundat
biomed
research
educ
grant
provid
abbott
laboratori
agouron
pharmaceut
inc
bristolmy
squibb
compani
f
hoffmannlaroch
glaxo
wellcom
merck
sharp
dohm
respiratori
virus
includ
respiratori
syncyti
viru
rsv
influenza
parainfluenza
virus
rhinovirus
import
caus
morbid
workrel
absente
medic
expenditur
well
establish
acut
respiratori
ill
caus
class
virus
commonli
warrant
hospit
certain
welldefin
popul
ie
young
infant
toddler
elderli
peopl
patient
chronic
obstruct
pulmonari
diseas
becom
clear
recent
year
infect
also
associ
signific
morbid
mortal
high
risk
popul
recipi
bone
marrow
organtranspl
patient
receiv
cytotox
chemotherapi
progress
develop
antivir
therapi
respiratori
viru
infect
constrain
number
obstacl
first
clinic
syndrom
caus
respect
virus
exhibit
consider
overlap
except
eg
detect
rsv
antigen
infant
rapid
specif
diagnost
assay
avail
secondli
role
immun
system
diseas
process
well
understood
secondari
effect
inflammatori
mediat
cytokin
lead
symptom
diseas
may
actual
problemat
viru
infect
thirdli
easili
administ
costeffect
efficaci
antivir
agent
wide
avail
possibl
except
amantadin
rimantadin
influenza
viru
infect
final
signific
mortal
respiratori
viru
infect
highrisk
popul
recent
appreci
howev
progress
antivir
therapi
respiratori
viru
infect
lag
behind
chemotherapeut
advanc
number
virus
eg
hiv
cmv
consider
advanc
develop
immunotherapi
immunoprophylaxi
prevent
respiratori
viru
infect
cheaper
easier
like
succeed
purpos
new
improv
vaccin
adjuv
avail
well
varieti
monoclon
polyclon
antibodi
passiv
immunoprophylaxi
addit
activ
matern
immun
last
trimest
pregnanc
may
prove
worthwhil
provid
passiv
immun
infant
new
develop
antivir
therapi
respiratori
viru
infect
summar
summari
restrict
rsv
influenza
rhinovirus
respiratori
virus
adenovirus
coronavirus
human
exclud
sinc
research
antivir
therapi
virus
yet
approach
clinic
develop
proteininhibitor
amantadin
rimantadin
licens
treatment
prophylaxi
influenza
viru
infect
agent
effect
prophylact
therapeut
agent
potenti
develop
viral
resist
drug
larg
hayden
hay
children
excret
resist
viru
treatment
drug
similarli
resist
viru
isol
immunocompromis
patient
treat
amantadin
rimantadin
sever
influenza
viru
infect
number
suffer
fatal
rimantadineresist
influenza
pneumonia
ribavirin
antivir
agent
licens
treatment
infect
rsv
also
show
antivir
effect
influenza
virus
vitro
anim
model
well
clinic
studi
gilbert
et
al
hosoya
et
al
rollin
et
al
rodriguez
et
al
use
ribavirin
infect
rimantadineresist
influenza
viru
current
studi
combin
treatment
rimantadin
ribavirin
show
synergist
antivir
activ
vitro
anim
model
hayden
report
benefici
hospit
patient
sever
influenza
pneumonia
novel
promis
agent
neuraminidaseinhibitor
still
clinic
develop
preclin
test
agent
show
potent
inhibit
viral
replic
appar
lower
potenti
develop
resist
vitro
amantadin
rimantadin
may
prove
major
advantag
wood
et
al
ryan
et
al
topic
administ
shown
highli
effect
prophylact
agent
therapeut
purpos
reduct
viral
titer
symptomatolog
observ
drug
given
within
h
onset
symptom
differ
placebo
viral
titer
symptom
observ
drug
administ
later
timepoint
anoth
drawback
may
limit
use
agent
poor
bioavail
drug
antivir
effect
observ
drug
administ
topic
rsv
caus
sever
pulmonari
diseas
newborn
children
high
risk
complic
rsv
diseas
eg
infant
congenit
heart
pulmonari
diseas
prematur
immunocompromis
infant
prevent
infect
immunoprophylaxi
infect
control
probabl
effect
treat
establish
infect
levin
hem
et
al
date
activ
immun
discourag
purpos
levin
hem
et
al
find
earli
studi
formalininactiv
vaccin
demonstr
rather
prevent
infect
vaccin
increas
sever
ill
children
becam
infect
substanti
influenc
progess
clinic
develop
rsv
vaccin
fulgin
et
al
kapikian
et
al
kim
et
al
passiv
immun
intraven
administ
polyclon
immunoglobulin
licens
young
children
high
risk
seriou
rsv
diseas
children
year
old
pulmonari
diseas
howev
prophylaxi
expens
practic
limit
sinc
requir
monthli
intraven
infus
h
durat
sever
monoclon
polyclon
antibodi
prepar
differ
rout
administr
eg
intramuscular
intranas
current
undergo
clinic
evalu
hem
et
al
taylor
et
al
addit
passiv
immun
infant
activ
immun
mother
may
benefici
bruhn
yeager
glezen
et
al
immunoglobulin
effect
treatment
establish
rsv
infect
either
previous
healthi
children
patient
high
risk
seriou
rsv
diseas
hem
et
al
licens
drug
rsv
diseas
guanosineanalogu
ribavirin
viral
resist
ribavirin
observ
presum
due
multipl
mechan
action
agent
patterson
fernandezlarsson
howev
antivir
potenc
drug
limit
role
ribavirin
treatment
remain
controversi
levin
current
standard
treatment
sever
rsv
diseas
highrisk
children
consist
aerosol
ribavirin
dosag
mgml
given
h
daili
long
durat
administr
number
disadvantag
includ
complianc
problem
health
hazard
exposur
drug
personnel
contamin
environ
reason
safeti
efficaci
high
dose
treatment
hday
studi
shown
safe
equal
effect
compar
standard
regimen
environment
contamin
reduc
immunocompromis
adult
rsv
pneumonia
carri
mortal
rate
approxim
untreat
englund
et
al
martin
et
al
hertz
et
al
harrington
et
al
suggest
uncontrol
case
seri
reduc
treatment
ribavirin
alon
hertz
et
al
harrington
et
al
improv
treatment
strategi
thu
clearli
need
patient
popul
combin
treatment
ribavirin
immunoglobulin
institut
earli
cours
infect
shown
promis
result
whimbey
et
al
small
uncontrol
studi
hospit
bone
marrow
transplantrecipi
rsv
pneumonia
treat
aerosol
ribavirin
intraven
immunoglobulin
mortal
rate
untreat
patient
patient
treat
late
cours
infect
ie
patient
alreadi
ventilationdepend
approach
stage
strikingli
patient
treat
earli
cours
diseas
mortal
rate
reduc
preliminari
result
show
similar
trend
leukem
patient
rsv
pneumonia
encourag
result
clearli
invit
studi
particular
combin
hospit
patient
sever
rsv
diseas
licens
treatment
parainfluenzaviru
infect
patient
high
risk
develop
complic
infect
identifi
includ
immunocompromis
children
patient
receiv
chemotherapi
recipi
bonemarrow
organtranspl
base
uncontrol
anecdot
data
current
experiment
treatment
option
parainfluenzaviru
infect
appear
ribavirin
administ
aerosol
bolu
continu
intraven
infus
gelfand
cobian
et
al
antibodi
prepar
parainfluenzaviru
avail
rhinovirus
import
caus
morbid
workand
schoolrel
absente
addit
asthmat
exacerb
may
associ
rhinoviru
infect
reason
effect
therapeut
regimen
would
desir
intranas
administ
recombin
truncat
intracellular
adhes
appear
promis
agent
current
undergo
clinic
test
martin
et
al
crumpet
al
ohlin
et
al
sinc
agent
show
enhanc
antivir
activ
vitro
combin
interferon
combin
may
also
warrant
clinic
evalu
herpesviru
famili
includ
virus
greatest
success
antivir
therapi
observ
howev
potenti
role
combin
antivir
treatment
limit
certain
manifest
herpesviru
infect
eg
cmv
diseas
immunocompromis
patient
neonat
cerebr
herp
simplex
viru
hsv
infect
sever
manifest
herpesviru
infect
selflimit
treat
effect
monotherapi
addit
aciclovir
sever
licens
investig
antivir
drug
avail
hsv
infect
includ
valaciclovir
penciclovir
famciclovir
cidofovir
foscarnet
valaciclovir
prodrug
aciclovir
readili
convert
aciclovir
cellular
hydrolas
advantag
valaciclovir
compar
aciclovir
lower
dose
frequenc
due
increas
oral
bioavail
versu
respect
soullawton
et
al
howev
clinic
efficaci
drug
treatment
mucocutan
hsv
infect
compar
penciclovir
prodrug
famciclovir
exhibit
similar
antivir
effect
aciclovir
phosphoryl
pathway
aciclovir
penciclovir
activ
triphosphatederiv
first
ratelimit
phosphorylationstep
mediat
viral
thymidin
kinas
common
caus
viral
resist
agent
defici
viral
enzym
pottag
kessler
cytosineanalogu
cidofovir
potent
antihsv
agent
requir
viral
thymidin
kinas
sinc
alreadi
monophosphoryl
therefor
may
use
treatment
aciclovirresist
hsv
infect
similarli
pyrophosph
analogu
foscarnet
directli
inhibit
viral
dna
polymeras
requir
phosphoryl
also
activ
aciclovirresist
viru
howev
viral
resist
foscarnet
even
dual
resist
foscarnet
aciclovir
report
safrin
et
al
immunocompet
adult
primari
recurr
mucocutan
hsv
infect
gener
respond
well
monotherapi
viral
resist
appear
pose
major
problem
therapeut
failur
patient
group
mostli
due
pharmocokinet
problem
resolv
switch
prodrug
combin
antivir
treatment
therefor
seem
warrant
immunocompet
adult
howev
may
role
combin
therapi
immunocompromis
patient
mucocutan
hsv
infect
patient
group
viru
load
high
spontan
clearanc
slow
manifest
infect
sever
combin
antivir
treatment
may
effect
reduc
viru
load
develop
viral
drug
resist
provid
signific
clinic
problem
patient
may
prevent
howev
clinic
studi
combin
antivir
treatment
patient
popul
perform
date
manifest
hsv
infect
potenti
amen
combin
antivir
treatment
neonat
infect
hsv
enceph
hsv
enceph
efficaci
aciclovir
monotherapi
may
hamper
limit
penetr
drug
central
nervou
system
famciclovir
shown
improv
cn
penetr
mice
compar
aciclovir
may
provid
good
altern
aciclovir
either
monotherapi
combin
treatment
regimen
final
combin
therapi
may
use
prevent
neonat
hsv
infect
shown
secondari
prophylaxi
aciclovir
alon
reduc
reactiv
rate
asymptomat
viral
shed
albeit
complet
spruanc
epstein
et
al
combin
treatment
may
result
complet
suppress
asymptomat
viral
shed
would
reduc
risk
hsv
transmiss
besid
combin
antivir
drug
combin
strategi
eg
antivir
immunomodul
antibodi
woundheal
enhanc
may
also
benefici
addit
modul
endogen
nucleotid
pool
antivir
effect
nucleosid
analogu
may
enhanc
combin
ribonucleotid
reductaseinhibitor
prichard
shipman
final
develop
vaccin
pursu
aggress
prevent
also
therapeut
purpos
aciclovir
valaciclovir
well
famciclovir
sorivudin
effect
acut
stage
herp
zoster
valaciclovir
famciclovir
never
compar
directli
appear
benefici
effect
postherpet
neuralgia
well
beutner
et
al
combin
strategi
aciclovir
newer
gener
analges
andor
corticosteroid
studi
shown
improv
qualiti
life
immunocompet
herp
zoster
patient
combin
antivir
treatment
may
benefici
immunocompromis
patient
herp
zoster
unrel
diseas
sever
dissemin
manifest
howev
clinic
trial
combin
antivir
treatment
herp
zoster
report
date
epsteinbarr
viru
caus
malign
lymphoma
immunocompromis
patient
may
theoret
prevent
antivir
combin
therapi
aciclovir
treatment
seem
effect
ebv
infect
luxton
et
al
compar
aciclovir
penciclovir
show
enhanc
activ
ebv
vitro
may
thu
potenti
candid
treatment
ebv
infect
prevent
lymphoma
bacon
boyd
studi
ongo
evalu
efficaci
ganciclovir
purpos
advanc
diagnosi
treatment
prophylaxi
cmv
infect
subject
separ
consensu
symposium
summari
publish
previous
journal
van
der
meer
et
al
neonat
infect
cmv
cmv
diseas
immunocompromis
patient
includ
transplant
recipi
hivinfect
person
import
target
improv
therapeut
modal
long
known
congenit
cmv
infect
sever
sequela
data
antivir
treatment
cmv
infect
larg
restrict
cmv
diseas
immunocompromis
patient
notabl
cmv
retin
hivinfect
patient
cmv
pneumon
transplant
recipi
current
avail
treatment
option
cmv
infect
cmv
dna
polymeraseinhibitor
ganciclovir
foscarnet
cidofovir
cmv
retin
three
drug
shown
effect
monotherapi
prolong
time
recurr
van
der
meer
et
al
howev
despit
chronic
mainten
therapi
relaps
retin
almost
invari
occur
part
may
due
acquisit
suboptim
intraocular
drugconcentr
system
therapi
problem
drug
deliveri
circumv
intravitr
administr
protect
develop
retin
contralater
eye
cmv
diseas
elsewher
anoth
import
caus
failur
mainten
therapi
develop
viral
resist
emerg
viru
variant
reduc
suscept
foscarnet
ganciclovir
prolong
monotherapi
well
document
associ
increas
plasma
cmv
load
treatment
boivin
et
al
ganciclovir
resist
confer
specif
mutat
gene
encod
viral
phosphotransferas
respons
first
phosphoryl
step
resist
also
result
mutat
gene
encod
viral
dna
polymeras
sinc
foscarnet
requir
phosphoryl
activ
cidofovir
alreadi
monophosphoryl
resist
drug
confer
amino
acid
chang
viral
dna
polymeras
dual
even
tripl
resist
respect
drug
commonli
observ
knox
et
al
sarasini
et
al
baldantini
et
al
van
der
meer
et
al
shown
high
level
low
level
ganciclovirresist
viru
variant
crossresist
cidofovir
indic
specif
mutat
polymerasegen
requir
cidofovirresist
high
level
ganciclovir
resist
addit
reduct
foscarnetsuscept
report
ganciclovirresist
viru
isol
resist
foscarnet
seem
develop
rapidli
patient
pretreat
ganciclovir
suggest
degre
crossresist
ganciclovir
foscarnet
well
interestingli
foscarnetresist
viru
appear
remain
sensit
cidofovir
case
low
level
ganciclovir
resist
viru
limit
efficaci
resist
made
cmv
retin
import
target
combin
antivir
treatment
combin
ganciclovir
foscarnet
cidofovir
show
addit
synergist
activ
vitro
combin
foscarnet
cidofovir
howev
synergist
nephrotox
preclud
latter
combin
system
therapi
combin
treatment
ganciclovir
foscarnet
significantli
prolong
progressionfre
interv
patient
relaps
retin
compar
monotherapi
either
ganciclovir
foscarnet
jacobson
et
al
studi
ocular
complic
aid
research
group
howev
visual
acuiti
assess
patient
receiv
combin
treatment
similar
patient
treat
monotherapi
furthermor
longer
infusiontim
increas
toxic
significantli
diminish
qualiti
life
patient
receiv
combin
combin
ganciclovir
foscarnet
polyclon
monoclon
antibodi
also
display
addit
synergist
activ
vitro
pollard
howev
placebocontrol
studi
compar
efficaci
ganciclovir
alon
combin
monoclon
antibodi
newli
diagnos
recurr
cmv
retin
show
addit
benefit
combin
treatment
studi
termin
prematur
increas
mortal
previous
treat
patient
receiv
combin
treatment
caus
remain
unknown
cmv
pneumon
enceph
also
potenti
target
combin
antivir
treatment
treatment
either
ganciclovir
foscarnet
much
impact
overal
surviv
cmv
pneumon
shepp
et
al
aschan
et
al
data
effect
combin
treatment
two
drug
efficaci
high
dose
intraven
immun
globulin
ivig
combin
ganciclovir
cmv
pneumonia
remain
controversi
emanuel
et
al
reed
et
al
verdonck
et
al
benefit
combin
initi
observ
appear
improv
surviv
compar
ganciclovir
alon
cerebr
cmv
infect
monotherapi
ganciclovir
foscarnet
best
stabil
diseas
process
suffici
penetr
bloodbrain
barrier
concern
develop
viral
resist
sinc
cn
diseas
often
occur
patient
receiv
longterm
mainten
therapi
cmv
retin
uncontrol
caseseri
suggest
benefit
combin
treatment
ganciclovir
foscarnet
treatment
cmv
enceph
ent
et
al
peter
et
al
conclus
monotherapi
current
avail
antivir
agent
treatment
cmv
diseas
immunocompromis
patient
gener
inadequ
combin
treatment
agent
may
result
increas
efficaci
increas
toxic
long
infus
time
also
reduc
qualiti
life
better
therapeut
option
clearli
need
number
new
anticmv
agent
includ
lobucavir
bispompmea
benzimidazol
well
number
antisens
oligonucleotid
current
clinic
develop
may
prove
promis
treatment
cmv
diseas
either
monotherapi
combin
exist
drug
pari
et
al
van
der
meer
et
al
identif
ebvlik
dna
sequenc
kaposi
sarcoma
ks
lesion
aid
patient
led
discoveri
new
viru
initi
term
ksassoci
herp
viru
kshv
also
call
offici
design
human
herpesviru
type
chang
et
al
sequenc
detect
ks
lesion
form
includ
classic
african
endemicand
hivassoci
ks
well
blood
lymphoid
tissu
unaffect
skin
ks
patient
ambroziak
et
al
boshoff
et
al
b
de
lelli
et
al
huang
et
al
schall
et
al
bigoni
et
al
humphrey
et
al
noel
et
al
oneil
et
al
longitudin
studi
suggest
presenc
blood
predict
subsequ
develop
ks
support
recent
serolog
studi
lefrer
et
al
lennett
et
al
besid
ks
presenc
also
associ
lymphoprolif
malign
especi
primari
bodi
cavitybas
lymphoma
angioimmunoblast
lymphadenopathi
castleman
diseas
cesarman
et
al
soulier
et
al
luppi
et
al
b
nador
et
al
otsuki
et
al
robert
et
al
said
et
al
sander
et
al
epidemiolog
studi
use
serolog
suggest
sexual
transmiss
like
consist
report
detect
sequenc
semen
prostat
gao
et
al
kede
et
al
lennett
et
al
monini
et
al
respect
treatment
role
pathogenesi
ks
clearli
need
elucid
sinc
express
gene
appear
limit
major
ks
lesion
suggest
predominantli
latent
infect
remain
studi
whether
antivir
therapi
benefici
establish
ks
decker
et
al
zhong
et
al
epidemiolog
studi
small
number
uncontrol
case
histori
suggest
foscarnet
may
reduc
risk
develop
ks
result
remiss
establish
ks
morfeldt
torssand
glesbi
et
al
base
report
sever
studi
current
ongo
evalu
efficaci
foscarnet
treatment
hivassoci
ks
recent
describ
cultur
system
may
enabl
vitro
screen
novel
antivir
agent
prophylaxi
treatment
ks
renn
et
al
infect
hepat
b
viru
hbv
result
develop
chronic
hepat
immunocompet
adult
immunocompromis
patient
patient
infect
birth
major
caus
death
worldwid
due
develop
cirrhosi
hepatocellular
carcinoma
progress
liver
diseas
driven
viral
replic
immunedestruct
hepatocyt
treatment
may
target
immun
system
inhibit
viral
replic
approv
treatment
chronic
hepat
b
interferon
alpha
predominantli
appear
act
amplifi
exist
immun
respons
result
immun
lysi
infect
hepatocyt
also
antivir
activ
approxim
patient
chronic
hbv
hepat
cirrhot
patient
respond
interferon
therapi
measur
clearanc
hbv
dna
patient
activ
hepat
reflect
increas
serum
transaminas
level
detect
hepat
antigen
low
hbv
dna
level
activ
liver
histolog
gener
show
best
respons
interferon
therapi
respons
observ
immunotoler
phase
infect
minim
hepat
brook
et
al
attempt
increas
therapeut
efficaci
combin
interferon
alpha
sever
immunomodulatori
agent
studi
combin
treatment
interferon
alpha
levamisol
interferon
gamma
proven
benefici
fattovich
et
al
bosch
et
al
ruizmoreno
et
al
consensu
role
pretreat
prednison
interferon
therapi
cohard
et
al
due
immunosuppress
activ
treatment
prednison
allow
increas
viral
replic
result
increas
express
antigen
stop
rebound
immun
lead
enhanc
elimin
infect
hepatocyt
subsequ
interferon
therapi
sever
studi
inde
shown
enhanc
viral
clearanc
interferon
therapi
withdraw
prednison
metanalysi
suggest
benefit
restrict
patient
low
alt
level
cohard
et
al
furthermor
risk
side
effect
higher
case
hepat
decompens
regimen
describ
sinc
hbvinfect
individu
elimin
viru
infect
clearli
differ
respect
lymphocyt
respons
hbv
immunostimul
specif
enhanc
cytotox
immun
respons
eg
potenti
benefici
treatment
hbv
infect
milich
et
al
phase
iii
studi
cytokin
current
ongo
besid
immunomodulatori
treatment
suppress
viral
replic
clearli
import
control
hbv
infect
lamivudin
penciclovir
pmea
nucleosid
analogu
inhibitor
viral
polymeras
potent
antivir
activ
vitro
heijtink
et
al
shaw
et
al
clinic
studi
suppress
hbv
dna
level
observ
virtual
patient
treat
lamivudin
dosag
excess
mgday
accompani
clearanc
hbe
antigen
patient
benham
et
al
dienstag
et
al
howev
observ
studi
lamivudin
treatment
relaps
viral
replic
usual
occur
follow
cessat
therapi
high
relaps
rate
explain
stabil
persist
coval
close
circular
intermedi
hbv
dna
cccdna
unaffect
act
transcript
templat
follow
withdraw
therapi
anim
model
studi
shown
level
cccdna
minim
affect
total
viral
replic
suppress
less
pekin
duck
greater
suppress
total
hbv
dna
level
accompani
declin
amount
cccdna
observ
treatment
penciclovir
high
dose
pmea
lamivudin
howev
even
month
penciclovir
therapi
minim
amount
cccdna
could
still
detect
duckhepatocyt
rapidli
return
pretreat
valu
follow
therapi
withdraw
achiev
effect
suppress
viral
replic
combin
antivir
therapi
may
result
reduct
rate
replenish
cccdna
rate
decay
combin
penciclovir
lamivudin
pmea
lesser
extent
lamivudin
pmea
show
addit
synergist
antivir
activ
vitro
may
thu
prove
effect
purpos
korba
combin
penciclovir
lamivudin
inde
result
substanti
reduct
total
intracellular
cccdna
level
vitro
either
agent
alon
anoth
concern
treatment
hbv
infect
may
warrant
combin
antivir
therapi
exist
extrahepat
extrahepatocyt
site
viral
replic
hbv
clear
differ
exampl
shown
duck
model
penciclovir
effect
extrahepat
site
viral
replic
pancrea
final
combin
antivir
therapi
may
effect
prevent
drug
resist
report
develop
monotherapi
lamivudin
penciclovir
ling
et
al
tippl
et
al
bartholomew
et
al
reduct
suscept
respect
agent
seem
confer
specif
mutat
hbv
polymeras
gene
associ
viral
breakthrough
treatment
besid
combin
two
antivir
agent
potenti
benefici
approach
therapi
combin
antivir
immunomodulatori
therapi
vitro
antivir
activ
interferon
alpha
enhanc
lamivudin
korba
howev
clinic
studi
combin
interferon
alpha
appear
confer
mark
addit
benefit
compar
lamivudin
alon
may
explain
lamivudineinduc
reduct
antigenexpress
cell
theoret
immun
amplif
may
nevertheless
import
cur
therapi
especi
chronic
persist
hepat
studi
viral
dynam
hbv
infect
indic
halflif
infect
cell
activ
diseas
approxim
day
due
immun
lysi
nowak
et
al
base
short
halflif
estim
case
complet
suppress
viral
replic
antivir
agent
erad
hbv
would
requir
approxim
year
treatment
could
theoret
shorten
less
year
immunomodulatori
agent
ad
howev
chronic
persist
hepat
immun
lysi
occur
halflif
infect
cell
calcul
markedli
longer
rang
day
long
halflif
cur
therapi
would
requir
mani
year
treatment
modul
immun
system
enhanc
immun
lysi
theoret
seem
import
hepat
c
viru
hcv
major
caus
chronic
hepat
develop
approxim
infect
individu
progress
liver
diseas
interferon
alpha
compris
mainstay
treatment
initi
respons
rate
interferon
therapi
hcv
infect
similar
hbv
infect
relaps
rate
follow
cessat
therapi
much
higher
sustain
respons
observ
approxim
patient
sherlock
furthermor
contrast
hbv
infect
respons
rate
cirrhot
patient
low
sinc
clinic
outcom
chronic
hcv
hepat
variabl
problem
manag
hcv
hepat
identif
patient
progress
sever
liver
diseas
thu
need
treatment
interferon
sever
factor
correl
increas
sever
diseas
includ
age
sex
mhc
class
ii
phenotyp
host
genotyp
quantiti
viru
sherlock
howev
factor
proven
particularli
use
manag
individu
patient
although
consensu
issu
treat
may
recommend
monitor
patient
regularli
includ
histolog
examin
yearli
interv
focu
treatment
patient
progress
moder
hepat
later
stage
diseas
cirrhosi
develop
rate
respons
treatment
sever
reduc
respons
rate
interferon
hcv
infect
rel
low
would
also
help
predict
patient
would
benefit
treatment
sever
host
viral
factor
associ
poor
respons
interferon
treatment
none
help
individu
patient
howev
shown
earli
chang
plasma
hcv
rna
load
first
week
treatment
predict
respons
treatment
hcv
rna
level
gener
declin
detect
level
within
day
respond
nonrespond
show
sustain
level
first
week
treatment
latter
group
treatment
could
stop
week
treatment
occurr
relaps
withdraw
therapi
initi
respond
predict
howev
sinc
relaps
gener
occur
within
month
complet
treatment
respons
patient
still
remiss
stage
like
sustain
view
rel
low
respons
rate
high
relaps
rate
associ
interferon
therapi
improv
therapeut
option
clearli
need
number
small
uncontrol
studi
strongli
suggest
enhanc
efficaci
combin
treatment
interferon
alpha
ribavirin
brillanti
et
al
braconi
et
al
brillanti
et
al
chemello
et
al
schvarcz
et
al
studi
rate
sustain
respons
doubl
compar
treatment
interferon
alon
promis
result
need
confirm
larger
random
placebocontrol
trial
current
progress
search
novel
antivir
agent
hinder
lack
tissu
cultur
system
anim
model
hcv
howev
character
structur
activ
viral
enzym
may
aid
identif
novel
inhibitor
viral
replic
viral
serin
proteas
may
prove
attract
target
structurebas
drug
design
hepat
viru
hdv
delta
agent
rna
viru
depend
hbv
replic
coinfect
hdv
hbv
gener
progress
chronic
hdv
hepat
superinfect
hdv
hbvinfect
patient
result
persist
hdv
infect
case
associ
rapidli
progress
liver
diseas
poor
prognosi
small
studi
interferon
treatment
shown
effect
decreas
hdv
rna
level
improv
liver
histolog
approxim
case
farci
et
al
rosina
cozzolongo
complet
treatment
relaps
occur
almost
invari
ribavirin
inhibit
hdv
replic
vitro
proven
benefit
vivo
monotherapi
rosina
cozzolongo
ongo
trial
evalu
whether
similar
hcv
infect
addit
ribavirin
interferon
treatment
increas
rate
respons
result
longer
last
benefit
efficaci
treatment
hiv
infect
monotherapi
limit
due
incomplet
suppress
viral
replic
develop
drug
resist
recent
year
limit
encourag
effort
pursu
aggress
develop
combin
antivir
treatment
strategi
evid
improv
efficaci
sever
combin
antivir
strategi
dispens
use
monotherapi
manag
infect
retrospect
current
knowledg
viral
dynam
infect
limit
efficaci
monotherapi
surpris
could
predict
high
rate
viral
replic
daili
product
virion
occur
throughout
cours
infect
ho
et
al
wei
et
al
perelson
et
al
coupl
high
mutabl
rt
persist
high
level
viral
replic
allow
continu
gener
mutat
viral
genom
includ
confer
drugresist
coffin
sinc
drugresist
viru
popul
thu
present
treatment
start
import
rational
combin
antivir
therapi
activ
broad
rang
preexist
mutant
equal
import
reason
combin
antivir
treatment
improv
suppress
viral
replic
therebi
diminish
likelihood
emerg
resistanceconf
mutat
treatment
drug
resist
develop
viral
replic
complet
suppress
ultim
goal
antivir
treatment
recent
studi
demonstr
level
circul
rna
repres
dynam
equilibrium
viru
product
clearanc
determin
earli
seroconvers
highli
predict
subsequ
cours
diseas
mellor
et
al
light
find
surpris
sever
studi
shown
correl
magnitud
durat
treatmentassoci
decreas
rna
load
improv
clinic
outcom
yerli
et
al
katzenstein
et
al
obrien
et
al
schooley
et
al
treatment
thu
aim
achiev
rna
level
low
possibl
long
possibl
sinc
sever
antiretrovir
combin
regimen
especi
involv
three
drug
recent
shown
result
sustain
reduct
plasma
viru
load
detect
level
cautiou
optim
manag
infect
justifi
potent
antivir
treatment
declin
plasma
viru
load
shown
follow
biphas
pattern
perelson
et
al
first
phase
reflect
high
viral
turnov
viru
load
decreas
low
level
within
day
follow
second
slower
phase
viru
load
declin
detect
level
durat
phase
appear
rang
week
thought
reflect
decay
rate
latent
infect
cell
base
durat
second
phase
decay
calcul
depend
total
number
latent
infect
cell
cell
durat
second
phase
week
complet
erad
viru
would
requir
approxim
year
fulli
suppress
treatment
calcul
made
assum
absenc
longliv
popul
infect
cell
potenti
present
could
account
third
slow
phase
decay
reignit
viral
replic
withdraw
suppress
therapi
concept
erad
challeng
sever
question
need
address
addit
possibl
presenc
longliv
viral
reservoir
clearli
longterm
followup
potent
antiretrovir
regimen
need
furthermor
although
promis
treatment
respons
observ
lymphoid
tissu
remain
studi
whether
sustain
complet
suppress
viral
replic
also
occur
solid
tissu
potenti
exist
sanctuari
site
viral
replic
may
clear
differ
eg
central
nervou
system
also
requir
investig
final
remain
seen
whether
complet
suppress
viral
replic
associ
complet
immunereconstitut
rate
progress
field
antiretrovir
treatment
last
year
consider
design
promis
combin
treatment
regimen
enabl
discoveri
larg
number
potent
antiretrovir
agent
current
six
revers
transcriptas
inhibitor
licens
us
includ
nucleosid
analogu
zidovudin
zalcitabin
didanosin
lamivudin
stavudin
nonnucleosid
inhibitor
nevirapin
well
potent
hiv
proteas
inhibitor
indinavir
ritonavir
saquinavir
addit
sever
proteas
inhibitor
nucleosid
analogueand
nonnucleosid
inhibitor
rt
undergo
clinic
evalu
includ
nelfinavir
delavirdin
lovirid
mention
sever
combin
regimen
shown
capabl
reduc
viru
load
plasma
undetect
level
extend
period
time
respect
tripl
combin
two
rt
inhibitor
one
hiv
proteas
inhibitor
appear
promis
although
potent
efficaci
also
observ
combin
three
rt
inhibitor
viz
zidovudin
didanosin
nevirapin
clinic
studi
evalu
efficaci
sever
dual
tripl
combin
current
progress
includ
studi
combin
therapi
proteas
inhibitor
ritonavir
saquinavir
addit
addit
antivir
activ
without
evid
cross
resist
may
benefici
effect
increas
plasma
saquinavir
level
due
induct
cytochrom
system
ritonavir
furthermor
studi
evalu
efficaci
tripl
combin
treatment
initi
earli
primari
infect
ongo
show
promis
result
final
studi
progress
evalu
whether
follow
cours
tripl
combin
therapi
complet
suppress
rna
level
sustain
less
toxic
expens
mainten
regimen
one
studi
actg
protocol
effect
complet
withdraw
therapi
also
assess
besid
combin
two
antiretrovir
agent
altern
combin
also
show
encourag
result
includ
addit
hydroxyurea
didanosin
enhanc
activ
latter
biron
et
al
addit
antivir
agent
shown
result
enhanc
increas
cell
count
kovac
et
al
immunomodulatori
agent
eg
interferon
proven
benefici
date
addit
caus
cutan
anogenit
wart
human
papilloma
virus
hpv
strongli
implic
caus
cervic
cancer
notabl
type
increas
evid
also
indic
associ
hpv
anogenit
squamou
cell
cancer
nonmelanoma
skincanc
malign
oral
caviti
esophagu
view
carcinogen
potenti
identif
antivir
agent
hpv
desir
howev
progress
field
hamper
lack
tissu
cultur
system
screen
compound
inhibitor
viral
replic
identifi
date
treatment
strategi
may
emerg
increas
knowledg
pathogenesi
hpv
infect
includ
potenti
use
interferon
antioxid
retinoid
number
cytokin
may
interfer
viral
replic
affect
transcript
pathway
kelloff
et
al
hemorrhag
fever
virus
caus
wide
spectrum
sever
clinic
syndrom
high
mortal
rate
pose
challeng
target
therapeut
intervent
two
class
group
virus
ie
hantavirus
filovirus
progress
field
antivir
therapi
made
hantavirus
caus
seriou
clinic
syndrom
associ
high
mortal
includ
hemorrhag
fever
renal
syndrom
hfr
caus
hantaan
seoul
puumulavirus
hantaviru
pulmonari
syndrom
hp
caus
recent
discov
sin
nombr
viru
treatment
hfr
intraven
ribavirin
proven
effect
reduc
risk
reach
oligur
phase
well
risk
hemorrhag
mortal
huggin
et
al
small
uncontrol
studi
compar
support
care
ribavirin
manag
hp
benefici
effect
ribavirin
treatment
observ
anon
howev
possibl
due
diagnost
delay
virtual
clinic
event
occur
suffici
ribavirin
level
attain
rariti
syndrom
sinc
outbreak
preclud
evalu
ribavirin
treatment
hp
besid
ribavirin
antivir
agent
hantavirus
identifi
sinc
discoveri
marburg
ebolavirus
caus
sever
document
deadli
outbreak
africa
addit
small
outbreak
ebola
viru
infect
document
us
itali
caus
import
primat
sourc
could
trace
singl
primat
export
philippin
research
develop
antivir
agent
ebola
viru
current
ongo
us
armi
medic
research
institut
random
screen
compound
ebola
viru
hardli
feasibl
high
laboratori
biosafeti
level
level
requir
filoviru
research
reason
virus
sought
could
predict
antivir
activ
compound
filovirus
view
similar
molecular
organ
paramyxovirus
includ
parainfluenza
viru
rsv
proven
good
candid
purpos
use
method
sever
class
compound
potenti
antifiloviru
activ
identifi
includ
rna
polymeras
inhibitor
inhibitor
enzym
sadenosylcystein
hydrolas
latter
class
agent
especi
subject
extens
research
newli
design
mous
model
ebola
viru
high
dose
prophylaxi
class
compound
shown
protect
infect
ebola
viru
prophylact
efficaci
high
antiebola
igg
titr
also
evalu
model
show
increas
surviv
efficaci
treatment
strategi
markedli
less
primat
obvious
similar
human
respect
pharmacokinet
pathogenesi
diseas
result
challeng
research
interest
may
point
way
effect
intervent
prophylaxi
deadli
viru
recent
year
limit
efficaci
current
antivir
treatment
strongli
encourag
continu
effort
identifi
improv
therapeut
option
sever
viral
infect
improv
efficaci
combin
antivir
therapi
establish
treatment
infect
increas
evid
indic
enhanc
benefit
combin
therapi
sever
viral
infect
well
consider
progress
field
antiretrovir
therapi
even
ignit
cautiou
optim
cur
therapi
infect
howev
longtern
followup
treatment
current
potent
antiretrovir
regimen
need
await
sever
question
regard
pathogenesi
infect
still
need
address
sever
virus
quest
novel
potent
antivir
agent
continu
discoveri
enabl
design
potenti
effect
combin
strategi
addit
challeng
research
progress
discov
antivir
agent
virus
treatment
yet
avail
hpv
filovirus
